Royalty Pharma plc (NASDAQ:RPRX – Get Rating) fell 3% on Friday . The company traded as low as $33.04 and last traded at $33.49. 891,173 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 1,902,270 shares. The stock had previously closed at $34.53. Wall Street Analysts Forecast Growth […]
The Manufacturers Life Insurance Company reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 16.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,996,437 shares of the biopharmaceutical company’s stock after selling 395,420 shares during the quarter. The […]
Royalty Pharma's (RPRX) new king has bought a big chunk of its shares and I'm buying, too, writes biotech investor Bret Jensen, who says the new CEO has hopeed on the stock of the buyer of biopharmaceutical royalties, which appears to be a solid value play in an overbought market..RPRX
StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX – Get Rating) from a hold rating to a buy rating in a research report report published on Friday. Several other equities analysts have also commented on the company. Morgan Stanley upped their price target on Royalty Pharma from $48.00 to $50.00 and gave the company an overweight […]
StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX – Get Rating) from a hold rating to a buy rating in a research report sent to investors on Friday morning. Several other equities research analysts have also issued reports on RPRX. UBS Group reduced their price objective on shares of Royalty Pharma from $51.00 to $48.00 and […]